1. HBW Insight
  2. >>Supply Chain

China Distribution Disruption Drags Kenvue Results

Activist Investor Starboard Files Nominations For Four Board Seats

 
• By Malcolm Spicer

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

(Source: Shutterstock)

Kenvue Inc.’s latest results show a moving target in the section of its business needing attention to spur sales growth as sales of the Listerine line and other essential health products dropped 4.1% in the fourth quarter while skin health and beauty product sales recovered to show slight growth.

Another target emerging for Kenvue management’s attention is Starboard Value and Opportunity Master Fund Ltd., owners of more than 22m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

Wellness Firms Targeting GLP-1 Patients’ Dietary Needs Keep Option To Provide Access To Oral Rx

Health and wellness brands and retail chains providing access to prescriptions for compounded GLP-1 drugs, most also offering supplements curated to help meet dietary needs of GLP-1 patients, are offering formulations in oral form as well as injection.

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By David Ridley

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 
• By Malcolm Spicer

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 
• By Malcolm Spicer

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

More from HBW Insight

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.

IBA Names Ooka Interim CEO; P&G, Sally Beauty Appoint Board Members – Appointments Roundup

The Independent Beauty Association announces CEO Don Frey will retire July 1 and will be replaced as interim CEO by Akemi Ooka, VP of global supply chain and sustainability resources.